2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-105281
    rel-(E)-BMY 21950 sodium 130200-44-1 98%
    rel-(E)-BMY 21950 sodium is the relative configuration of BMY 21950 (HY-105281A). BMY 21950 is an HMG-CoA reductase inhibitor. BMY 21950 inhibits hepatic cholesterol synthesis.
    rel-(E)-BMY 21950 sodium
  • HY-105286
    BI-135585 1114561-85-1 98%
    BI-135585 is a potent, selective and orally active 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1) inhibitor with an IC50 of 13 nM. BI-135585 exhibits >1000-fold selectivity over other hydroxysteroid dehydrogenases. BI-135585 can be used for type 2 diabetes research.
    BI-135585
  • HY-105291
    CKD-711 445010-62-8 98%
    CKD-711 is an orally active aminooligosaccharide α-glucosidase inhibitor with an IC50 of 78 μg/mL. CKD-711 also inhibits porcine intestinal maltase and sucrose with IC50 values of 2.5 and 0.5 μg/mL. CKD-711 shows selective antibacterial activity against Comamonas terrigena. CKD-711 can be used for the researches of infection and metabolic disease, such as diabetes.
    CKD-711
  • HY-105316
    CP-800569 263262-73-3 98%
    CP-800569 is an orally active cholesteryl ester transfer protein (CETP) inhibitor. CP-800569 can decrease low-density lipoprotein and postprandial triglyceride and increase high-density lipoprotein. CP-800569 can be used for the research of metabolic disease.
    CP-800569
  • HY-105333
    KC-11458 151052-43-6 98%
    KC-11458 is a motilin agonist. KC-11458 can accelerate gastric emptying.
    KC-11458
  • HY-105410
    OT-7100 174858-27-6 98%
    OT-7100 is an orally active analgesic agent. OT-7100 inhibits hyperalgesia possibly by enhancing adenosinergic neurotransmission in the dorsal horn. OT-7100 can be used for the researches of inflammation, neurological and metabolic disease such as diabetes2].
    OT-7100
  • HY-105485
    FR-62765 105346-34-7 98%
    FR-62765 is a derivative of WF-3681. FR-62765 can significantly inhibit the accumulation of sorbitol in the sciatic nerve and the decrease of motor nerve conduction velocity in the tail of diabetic neuropathy rats, which can be used in the research of diabetic neuropathy.
    FR-62765
  • HY-105526
    Trimethylcolchicinic acid 3482-37-9 98%
    Trimethylcolchicinic acid (Desacetylcolchiceine; N-Deacetylcolchiceine) is a colchicine analogue. Trimethylcolchicinic acid promotes the production of chondroitin sulfate in L cells and inhibits the production of dermatan sulfate. Trimethylcolchicinic acid reduces liver fibrosis and cholestasis induced by long-term biliary obstruction in rats. Trimethylcolchicinic acid has potential for use in research on diseases such as liver fibrosis, gout, and cancer.
    Trimethylcolchicinic acid
  • HY-105528
    MDL-25637 104343-33-1 98%
    MDL-25637 is an α-glucosidase inhibitor. MDL-25637 can inhibit the activity of sucrose enzyme, maltase, isomaltase, glucose amylase, and trehalose in the intestinal tract of rats. MDL-25637 can be used in the research of diabetes.
    MDL-25637
  • HY-105577
    Picilorex 62510-56-9 98%
    Picilorex is an active compound. Picilorex can be used for the research of anorectic.
    Picilorex
  • HY-105608
    Narceine 131-28-2 98%
    Narceine (Narcein), a quinolone derivative, is an opium alkaloid with anti-diabetic property.
    Narceine
  • HY-10585B
    Valproic acid sodium (2:1) 76584-70-8 98%
    Valproic acid (VPA) sodium (2:1) is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium (2:1) activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium (2:1) is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches.
    Valproic acid sodium (2:1)
  • HY-105894
    SC-42867 102251-91-2 98%
    SC-42867 is a PGE2 antagonist. SC-42867 can be metabolized in the liver through oxidative N-dealkylation, aromatic hydroxylation, and binding reactions. SC-42867 can be used for research on metabolic conditions.
    SC-42867
  • HY-105955
    FPL 14294 154132-95-3 98%
    FPL 14294 is a intranasally active anorectic agent and a cholecystokinin octapeptide (CCK) analog with enhanced metabolic stability. FPL 14294 induces satiety in many species and can be utilized in relevant research.
    FPL 14294
  • HY-105961
    F 2833 107430-45-5 98%
    F 2833 is a lipid-lowering agent. F 2833 can reduce the levels of cholesterol, triglycerides, and plasma phospholipids. F 2833 can be used for research on diseases such as hyperlipidemia.
    F 2833
  • HY-105975
    Ciclazindol 37751-39-6 98%
    Ciclazindol (WY-23409) is an orally active antidepressant. Ciclazindol can inhibit the reuptake of norepinephrine. Ciclazindol also exhibits effects of lowering blood glucose, suppressing appetite and reducing weight. Ciclazindol can be used in the research of diseases such as depression and obesity.
    Ciclazindol
  • HY-106027
    Romazarit 109543-76-2 98%
    Romazarit (RO 31-3948) is an anti-inflammatory agent with antirheumatic effect. Romazarit exhibits PPARα agonist activity. Romazarit (30 mg/kg) inhibits the development of hindpaw inflammation in an adjuvant arthritis model.
    Romazarit
  • HY-106054
    Nocloprost 79360-43-3 98%
    Nocloprost, a prostaglandin E2 (PGE2) analog, is an orally active EP1- and EP3-receptor agonist. Nocloprost inhibits evoked [3H]ACh release. Nocloprost has gastroprotective and ulcer-healing properties. Nocloprost accelerates the healing of chronic gastric ulcerations and enhances mucosal growth in rats.
    Nocloprost
  • HY-106106
    Tiqueside 99759-19-0 98%
    Tiqueside (CP‐88,818) is an orally active cholesterol absorption inhibitor. Tiqueside inhibits absorption of both dietary cholesterol and endogenous cholesterol excreted into the intestinal lumen via the bile. Tiqueside can be used in the research of hypercholesterolemia.
    Tiqueside
  • HY-106110
    OP-2507 101758-79-6 98%
    OP-2507 is a prostacyclin analog. OP-2507 can increase brain glucose levels in mice, suppress the breakdown of energy metabolism under hypoxic conditions, and has a protective effect against changes in cyclic nucleotides in hypoxic brain tissue (specifically, an increase in cyclic AMP and a decrease in cyclic GMP). OP-2507 provides protective effects against brain hypoxia and edema.
    OP-2507
Cat. No. Product Name / Synonyms Application Reactivity